Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Genus's bottom line hit by write-downs

(Sharecast News) - Genus reported a big drop in full-year profits as a result of write-downs. But chief executive officer Jorgen Kokke sounded a positive note: "Genus achieved a strong first half with broad-based growth across PIC and a significant improvement in ABS profitability.

"We are particularly pleased to have achieved very strong cash generation in the period through significantly enhanced working capital management and disciplined investments in the business."

Kokke also highlighted the recent addition of seven new royalty customers in the People's Republic of China and reiterated that it expected America's FDA to approve its two PRP facilities over the course of 2025.

The animal breeding and genetics specialist reported a 1% rise in revenues to reach £336.4m.

Yet its statutory profit before tax fell by 77% to £3.3m, on account of a non-cash fair value IAS41 valuation adjustment on its biological assets, mainly bovine.

In adjusted terms on the other hand, free cash flow swung from -£12.bn in 2023 to £10.3bn last year.

Net debt as a proportion of operating profits in EBITDA terms was unchanged at 2.0 times.

The interim dividend was kept at 10.3p per share and was covered 2.2 times over by adjusted earnings.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.